Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone Hettmer

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
Cancer Medicine|March 27, 2015
Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population DatabasePhilip J Lupo, Heather E Danysh, Sharon E Plon, et al.
Pediatric Blood & Cancer|February 15, 2019
Rhabdomyosarcoma diagnosed in the first year of life: Localized, metastatic, and relapsed disease. Outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS)Monika Sparber-Sauer, Sabine Stegmaier, Christian Vokuhl, et al.
Pediatric Blood & Cancer|December 10, 2019
Endothelial cell malignancies in infants, children and adolescents: Treatment results of three Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registryMonika Sparber-Sauer, Ewa Koscielniak, Christian Vokuhl, et al.
Cancer|February 21, 2018
Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology GroupLisa A Teot, Michaela Schneider, Aaron R Thorner, et al.
Pediatric Blood & Cancer|August 4, 2021
Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumorsMona Steinbügl, Karolina Nemes, Pascal Johann, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2022
Congenital spindle cell rhabdomyosarcoma: An international cooperative analysisSarah Whittle, Rajkumar Venkatramani, Anton Schönstein, et al.
Cancer Cell|August 5, 2014
The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formationAnnie M Tremblay, Edoardo Missiaglia, Giorgio G Galli, et al.
Familial Cancer|September 5, 2020
Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working GroupSimone Hettmer, Guillaume Dachy, Guido Seitz, et al.
Cancer|June 20, 2020
Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance surveyNathalie Rippinger, Christine Fischer, Markus W Haun, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 29, 2025
EPICYCLE: A confirmatory preclinical study of the anti-rhabdomyosarcoma efficacy of BET bromodomain and cyclin-dependent kinase 9 inhibitorsBernhard Haller, Günther H S Richter, Marco Wachtel, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Cancer Medicine|March 27, 2015
Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population DatabasePhilip J Lupo, Heather E Danysh, Sharon E Plon, et al.
Pediatric Blood & Cancer|February 15, 2019
Rhabdomyosarcoma diagnosed in the first year of life: Localized, metastatic, and relapsed disease. Outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS)Monika Sparber-Sauer, Sabine Stegmaier, Christian Vokuhl, et al.
Pediatric Blood & Cancer|December 10, 2019
Endothelial cell malignancies in infants, children and adolescents: Treatment results of three Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registryMonika Sparber-Sauer, Ewa Koscielniak, Christian Vokuhl, et al.
Cancer|February 21, 2018
Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology GroupLisa A Teot, Michaela Schneider, Aaron R Thorner, et al.
Pediatric Blood & Cancer|August 4, 2021
Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumorsMona Steinbügl, Karolina Nemes, Pascal Johann, et al.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2022
Congenital spindle cell rhabdomyosarcoma: An international cooperative analysisSarah Whittle, Rajkumar Venkatramani, Anton Schönstein, et al.
Cancer Cell|August 5, 2014
The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formationAnnie M Tremblay, Edoardo Missiaglia, Giorgio G Galli, et al.
Familial Cancer|September 5, 2020
Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working GroupSimone Hettmer, Guillaume Dachy, Guido Seitz, et al.
Cancer|June 20, 2020
Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance surveyNathalie Rippinger, Christine Fischer, Markus W Haun, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 29, 2025
EPICYCLE: A confirmatory preclinical study of the anti-rhabdomyosarcoma efficacy of BET bromodomain and cyclin-dependent kinase 9 inhibitorsBernhard Haller, Günther H S Richter, Marco Wachtel, et al.
Pageof 8